Skip to content

Article

Ares and HPS Could Provide $3B to Back Carlyle’s Potential Acquisition of Baxter’s Kidney-Care Unit; Pricing Indicated at SOFR+500 Bps

Share on X (opens in a new window) Share on Facebook (opens in a new window) Share on LinkedIn (opens in a new window)

 

 

Relevant Document:
Form 8-K

Private lenders Ares Management and HPS Investment Partners are in talks with private equity firm Carlyle to provide roughly $3 billion debt financing to back Carlyle’s potential acquisition of Baxter International’s kidney-care business, according to sources.

The debt financing package would include a $2.5 billion unitranche loan and a $450 million revolver, according to sources. Pricing on the facility is indicated at about SOFR+500 bps, according to sources. Terms of the transaction are evolving and they might change, a source cautioned.

As of March 31, Baxter International had $13.73 billion of long-term debt and current maturities, including lease obligations with over $3 billion in cash and cash equivalents. The company had $130 million outstanding under one tranche of a term loan due 2024 and $1.64 billion outstanding under the another term loan credit facility due 2026, according to Securities and Exchange Commission filings. A list of Baxter International’s existing CLO holders can be found in Reorg’s CLO database HERE.

The Wall Street Journal and Reuters reported earlier this month that Carlyle was in advanced talks to acquire Baxter’s kidney-care unit, Vantive, for more than $4 billion, including debt.

Baxter International announced its plan to explore a sale of its kidney-care business in March. The company is committed to completing the separation in the second half of 2024, as shown in an SEC filing.

A separate SEC filing in mid-July shows that the healthcare company previously arranged senior unsecured term loans with JPMorgan Chase Bank and other banks for up to $2.05 billion. Part of the funds will be used for U.S. tax payments related to the planned separation of Baxter’s kidney-care business.

Fitch Ratings said in a commentary in June that the divestiture of the kidney-care unit would weaken Baxter International’s scale, diversification and market strength, given its significant revenue from the renal care sector. Fitch has rated Baxter’s debt BBB-, but the ratings agency does not provide any other ratings and analysis.

Vantive had total revenue of roughly $4.5 billion in 2023, along with more than 22,000 employees, according to the company’s site.

Headquartered in Illinois, Baxter International primarily focuses on products to treat kidney disease and other chronic and acute medical conditions.

In May 2023, the company sold its BioPharma Solutions business to private equity firms Advent International and Warburg Pincus for $4.25 billion, according to an announcement.

Ares declined to comment. Carlyle, HPS Investment Partners and Baxter International did not respond to a request for comment.

This publication has been prepared by Octus Intelligence, Inc. or one of its affiliates (collectively, "Octus") and is being provided to the recipient in connection with a subscription to one or more Octus products. Recipient’s use of the Octus platform is subject to Octus Terms of Use or the user agreement pursuant to which the recipient has access to the platform (the “Applicable Terms”). The recipient of this publication may not redistribute or republish any portion of the information contained herein other than with Octus express written consent or in accordance with the Applicable Terms. The information in this publication is for general informational purposes only and should not be construed as legal, investment, accounting or other professional advice on any subject matter or as a substitute for such advice. The recipient of this publication must comply with all applicable laws, including laws regarding the purchase and sale of securities. Octus obtains information from a wide variety of sources, which it believes to be reliable, but Octus does not make any representation, warranty, or certification as to the materiality or public availability of the information in this publication or that such information is accurate, complete, comprehensive or fit for a particular purpose. Recipients must make their own decisions about investment strategies or securities mentioned in this publication. Octus and its officers, directors, partners and employees expressly disclaim all liability relating to or arising from actions taken or not taken based on any or all of the information contained in this publication. © 2026 Octus. All rights reserved. Octus(TM) and the Octus logo are trademarks of Octus Intelligence, Inc.